Australia, CAR - T Cell therapy, CAR T Therapy, Cartherics
Peter MacCallum Cancer Centre and Cartherics will collaborate on ovarian cancer CAR-T cell therapy
March 2023: Peter MacCallum Cancer Centre (Peter Mac) in Australia and Cartherics Pty Ltd have entered into a collaborative development programme agreement (CDPA) to develop CTH-002 for the treatment of ovarian cancer. The cli..
CADD522, Journal of Bone Oncology, University of East Anglia’s Norwich Medical School
New drug for primary bone cancer in children
March 2023: The scientists who developed a new drug that may be effective against all major types of primary bone cancer in children have called it "the most significant drug discovery in the field in nearly half a century." T..
Arcellx, CAR T Therapy, CART DDBCMA, chimeric antigen receptor, Kite Pharma, multiple myeloma
KITE AND ARCELLX CLOSE AGREEMENT TO CO-DEVELOP AND CO-COMMERCIALIZE LATE-STAGE CLINICAL CART-DDBCMA IN MULTIPLE MYELOMA
SANTA MONICA, Calif. & REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announced global strategic..
Beijing, CARTITUDE-4, CARVYKTI, China, ciltacabtagene autoleucel, Clinical trials, Legend biotech, refractory multiple myeloma, Shanghai
Legend Biotech Announces Phase 3 CARTITUDE-4 Study of CARVYKTI®(ciltacabtagene autoleucel) Has Met Its Primary Endpoint in the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
JANUARY 27, 2023—Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that ..
Beijing, Biotechnology, Cell therapy, Cellular therapy, China, Cilta-Cel, ciltacabtagene autoleucel, Legend biotech
Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China
SOMERSET, N.J.—JANUARY 2, 2023— Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, ann..
China, Clinical trials, hepatocellular carcinoma, JW Therapeutics, Shanghai
JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, CHINA, February 28, 2023 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the init..
American Society of Hematology, Carteyva, China, JW Therapeutics, relmacabtagene autoleucel
JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting
SHANGHAI, CHINA, December 12, 2022 An independent and creative biotechnology company called JW Therapeutics (HKEX: 2126) focuses on developing, manufacturing, and selling cell immunotherapy products. At the 64th American Society ..
Cell therapy, China, JW Therapeutics, Shanghai
JW Therapeutics Announces That Its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients
SHANGHAI, CHINA, November 9, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that as of N..
2seventy bio, China, Immunotherapy, JW Therapeutics, Partnership
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T-cell-based Immunotherapies
SHANGHAI, CHINA and CAMBRIDGE, MASSACHUSETTS, US, October 27, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherap..
Carteyva, JW Therapeutics, lymphoma, refractory follicular lymphoma, RELIANCE study, relmacabtagene autoleucel
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, CHINA, October 10, 2022 - JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing, and commercializing cell immunotherapy products, announced that the Na..